cystic fibrosis – Medxy AI

Transformative Survival Gains in Cystic Fibrosis: A Population-Level Evaluation of CFTR Modulator Therapy Effectiveness

By MedXY 05/14/2026

A large-scale retrospective study using US CFF Registry data reveals that CFTR modulator therapy reduces the hazard of death by 66% over an eight-year period, marking a significant milestone in cystic fibrosis clinical outcomes and life expectancy.

news Psychiatry Respiratory

The Human Cost of Respiratory Care: Why Multidisciplinary Teams Cannot Shield Physicians from Burnout

By MedXY 03/19/2026

A comprehensive study of 569 cystic fibrosis professionals identifies physicians as the group most vulnerable to burnout, emotional exhaustion, and depersonalization. The research highlights administrative burden as a primary driver and calls for urgent systems-level reforms to protect the respiratory workforce.

news Pediatrics Respiratory

Beyond the Pill: Why Elexacaftor/Tezacaftor/Ivacaftor Alone Is Not Enough for Peak Physical Fitness in Cystic Fibrosis

By MedXY 02/04/2026

An Italian multicentric study reveals that while ETI therapy significantly improves several health markers in Cystic Fibrosis patients, its impact on peak aerobic capacity is modest, emphasizing the indispensable need for structured physical exercise alongside pharmacological treatment.

Clinical Updates Diabetes & Endocrinology news Specialties

Triple Therapy Enhances Glycemic Control in Cystic Fibrosis Patients with Abnormal Glucose Tolerance

By MedXY 09/02/2025

Elexacaftor-tezacaftor-ivacaftor significantly improves glucose tolerance, lowers A1c and sweat chloride levels, and demonstrates safety in cystic fibrosis patients with impaired glucose tolerance or cystic fibrosis-related diabetes over 48 weeks.